诺和诺德披露10月12-16日股票回购交易明细，属既有150亿丹麦克朗回购计划的例行Safe Harbour进度报告

Bagsværd, Denmark, 19 October 2026
– On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.
Since the announcement 12 October, the following transactions have been made:
Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement
23,090,000
6,758,876,433
12 October 2026
250,000
257.41
64,351,856
13 October 2026
245,000
258.17
63,251,159
14 October 2026
245,000
254.86
62,441,019
15 October 2026
245,000
259.36
63,543,405
16 October 2026
240,000
260.67
62,560,442
Accumulated under the programme
24,315,000
7,075,024,314
The details for each transaction made under the share repurchase programme are published on
novonordisk.com
.
With the transactions stated above, Novo Nordisk owns a total of 53,114,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.2% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 16 October 2026, Novo Nordisk has since 4 February 2026 repurchased a total 39,074,179 B shares at an average share price of DKK 278.32 per B share equal to a transaction value of DKK 10,875,024,304.
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit
novonordisk.com
and follow us on
Instagram
,
LinkedIn
,
TikTok
,
Facebook
,
X
and
YouTube
.
Contacts for further information
Novo Nordisk Media:
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com
Novo Nordisk Investors:
Michael Novod
+45 3075 6050
nvno@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com
Max Ung
+45 3077 6414
mxun@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com
Company announcement No 62 / 2026
Attachments
20261019.Safe Harbour
20261019_Safe harbour transaction details